CELC’s REVTORPYK gains approval; second-line breast cancer launch planned this quarter
REVTORPYK has received approval for second-line metastatic breast cancer. Commercial launch is planned this quarter, and a supplemental NDA for PIK3CA-mutant patients is under review, supported by strong clinical data and broad market strategy.